Vascular Biology |
From the Department of Pharmacology and Toxicology (X.T., B.B.H., K.N., C.J.H., W.B.C.), Medical College of Wisconsin, Milwaukee; and the Institute of Biochemistry (H.K.), University Medicine BerlinCharité, Berlin, Germany.
Correspondence to William B. Campbell, Department of Pharmacology and Toxicology, Medical College of Wisconsin, 8701 Watertown Plank Rd, Milwaukee, WI 53226. E-mail wbcamp{at}mcw.edu
| Abstract |
|---|
|
|
|---|
Methods and Results RT-PCR using 12-lipoxygenase/15-LO specific primers resulted in a 572-bp product with a sequence identical to 15-LO-I from rabbit aorta. A RT-PCR/restriction digest strategy excluded expression of 12-lipoxygenase. Immunoblotting revealed 15-LO-I expression in rabbit endothelial and smooth muscle cells. Aortic homogenates and cytosolic fractions metabolize AA to 15(S)-hydroxyeicosatetraenoic acid and linoleic acid to 13(S)-hydroxyoctadecadienoic acid. This activity was blocked by LO inhibitors. The kinetic characteristics (Michaelis constant of aortic 15-LO is 2.2±0.3 µmol/L for AA and 23.5±3.3 µmol/L for linoleic acid) of aortic 15-LO were similar to those of the purified 15-LO-I. An antisense oligonucleotide inhibited 15-LO-I expression in rabbit aorta. Indomethacin and nitro-L-arginine-resistant relaxations to acetylcholine were inhibited by 15-LO-I antisense oligonucleotide but not by the scrambled oligonucleotide.
Conclusions 15-LO-I is expressed in rabbit aortic endothelium and is important in endothelium-dependent regulation of vascular tone.
15-LO-I is expressed in rabbit aorta. 15-LO regulates vasodilatory eicosanoid synthesis and vascular tone.
Key Words: endothelium arachidonic acid 15-lipoxygenase endothelium-derived hyperpolarizing factor
| Introduction |
|---|
|
|
|---|
In humans, there are 2 15-LO isozymes (15-LO-I and 15-LO-II) originating from 2 different genes.8,9 15-LO-I was cloned from rabbit reticulocytes10 and human leukocytes and oxygenates AA to 15(S)-hydroperoxyeicosatetraenoic acid (90%) and 12(S)-hydroperoxyeicosatetraenoic acid (10%).8 It is expressed in various cell types, such as reticulocytes, airway epithelial cells, and eosinophilic granulocytes.11 It uses as substrates AA, linoleic acid (LA),12,13 or 2-arachidonoylglycerol (2-AG),14 as well as phospholipids or cholesterol esters containing AA or LA.15,16 15-LO-I is predominately localized in the cytosol; however, a variable proportion of the enzyme may be membrane bound.17 15-LO-I has been implicated in many physiological and pathological events. Distinct from 15-LO-I, 15-LO-II selectively metabolizes free fatty acids and prefers AA to LA as a substrate.9,18 The cDNA sequences for human 15-LO-I and 15-LO-II share a low degree of identity (36%). These distinct enzymatic properties, as well as the tissue- and cell-specific expression patterns, suggest different biological functions of the 15-LO isoforms. Rabbits express 15-LO-I and a 12-LO in the same tissue. Both enzymes share a 99% amino acid homology with 4 amino acid exchanges. One of these exchanges (Phe353Leu) is responsible for the different positional specificities for oxygenation of the 2 enzymes.19
Rabbit aorta and cultured ECs convert AA to 15-HPETE and 15-HETE.5,7,20 However, the cellular expression patterns of the enzyme(s) responsible for the enzymatic properties of aortic 15-LO are still not clear. Also, because LO inhibitors also block 5-LO, 12-LO, 15-LO, and possibly other pathways of AA metabolism,21 a more specific approach is needed to study 15-LO function. Here, we report the expression of 15-LO-I in rabbit aorta and exclude significant expression of 12-LO. We also demonstrated clear similarities in the basic kinetic characteristics of 15-LO from aortic cytosol and purified rabbit reticulocyte 15-LO-I. These data support our conclusion that the 15-LO activity of rabbit aorta is attributable to 15-LO-I. Moreover, using antisense oligonucleotides, we suppressed the expression of 15-LO-I in isolated rabbit aorta and decreased the relaxation responses to acetylcholine. These studies provide evidence for the important role of 15-LO-I in regulation vascular tone in the rabbit aorta.
| Methods |
|---|
|
|
|---|
Western Immunoblotting Assay
Protein lysates (30 µg) were loaded in each lane and separated by SDS gel electrophoresis as described previously.17,22 After being transferred to nitrocellulose membranes, membranes were exposed to the guinea pig antirabbit 15-LO-I antibody (1:1000 overnight at 4°C and then rinsed repeatedly). Membranes were then incubated with 1:2000 goat antiguinea pig IgG (horseradish peroxidase-conjugated, Jackson Immunoresearch) for 1 hour at room temperature and then rinsed. Immunoreactive bands were identified using the chemiluminescence detection.
RT-PCR
Total RNA was prepared from rabbit aortic tissue by using Trizol total RNA isolation reagent (Life Technologies) as described previously.23 PCR reactions were performed using PCR Supermix kit (Life Technologies). The 50-µL PCR mixture consisted of primers [0.2 µmol/L, High Fidelity buffer (1x), 2'-deoxynucleoside 5'-triphosphate (1 µmol/L), MgSO4 (1 mmol/L), and Platinum Taq (GIBCO)]. The forward primer was made against 1 to 20 nucleotide (nt) of rabbit reticulocyte 15-LO complete mRNA sequence: 5'- ACAAGGCGTGCAACGACC CT-3', and reverse primer, against 592 to 621 nt, 5'-CCAGGGAGCAGAACATTGAGTC CTT-3'. The program for the thermocycler was 94°C for 30 s, 58°C for 1 minute, and 72°C for 1.5 minutes, repeated 30 times followed by final extension at 72°C for 7 minutes. PCR products were separated by 1% agarose gel electrophoresis and visualized by ethidium bromide staining. The PCR band was isolated from the gel, excised, and subcloned into TOPO2.1 TA cloning vector (Invitrogen) and sequenced.
RT-PCR/Restriction Cleavage Strategy
Total RNA (1 µg) was reverse transcribed at 37°C for 170 minutes in 45 µL 28 mmol/L Tris-HCl buffer (pH 8.3) containing 1.7 mmol/L MgCl2, 42 mmol/L KCl, 5.5 mmol/L DTT, 0.277 mmol/L of 2'-deoxynucleoside 5'-triphosphate, 100 µg/mL BSA, 11 ng/µL of oligo d(T)18 primer, and 200 units of reverse transcription. The PCR sample (total volume of 25 µL) consisted of a 10 mmol/L Tris-HCl buffer (pH 9.0) containing 3 µL of reverse transcription sample, 4 mmol/L MgSO4, 100 nmol/L forward (5' TGG CTG CCC CGC TGG TCA TG 3') and reverse (5' CCT GGC GCG GAC GTT GAT CTC 3') primers, 120 µmol/L 2'-deoxynucleoside 5'-triphosphate, and 1 unit of Pyra exo() DNA polymerase. The PCR program consisted of 2 minutes at 94°C, 45 s at 95°C, 30 s at 60°C, and 2 minutes at 68°C. After 34 cycles of amplification, a postconditioning phase (10 minutes at 70°C) was carried out, and the storage was at 4°C. PCR products were digested at 60°C for 3 hours in 10 µL of 10 mmol/L Tris-HCl buffer (pH 7.9) containing 50 mmol/L NaCl, 10 mmol/L MgCl2, 1 mmol/L DTT, 100 µg/mL BSA, and 2 units of BstNI. Digestion products were resolved by electrophoresis in a 2% agarose gel.
15-LO Enzymatic Activity
Cytosolic proteins in HEPES buffer (0.2 mg/2 mL) were incubated with LA or AA (103 to 105 mol/L) at 23°C for various times. Also, cytosolic proteins were incubated in HEPES buffer with 107 to 104 mol/L of AA or LA at 23°C for 20 minutes. The reaction was terminated with glacial acetic acid (40 µL) and 95% ethanol (0.3 mL), 8-HETE (100 ng) was added, and lipids were extracted by solid phase extraction.22 13-(S)-hydroxyoctadecadienoic acid (13-HODE), 8-HETE, and 15-HETE were resolved and measured by reverse-phase (RP) high-performance liquid chromatography (HPLC) on a Phenomenex Kromasil C18 column (2.0x250 mm) with a Hewlett-Packard 1090 liquid chromatograph. The flow rate was 0.2 mL/min. Solvent A was deionized water with 0.1% glacial acetic acid, and solvent B was acetonitrile with 0.1% glacial acetic acid. The program consisted of a linear gradient from 55% to 60% B over 10 minutes, 10 minutes at 60% B, a linear gradient from 60% to 75% B over 15 minutes, and a linear gradient of 75% to 100% over 5 minutes. Absorbance at 235 nm was monitored with a diode array UV detector and was recorded and analyzed with Chemstation software. The amount of 15-HETE or 13-HODE was measured by comparing the peak area to the internal standard 8-HETE.
Liquid Chromatography-Electrospray Ionization-Mass Spectrometric Analysis
Samples were analyzed on Agilent 1100 LC/MSD, as described previously.24 Metabolites were separated by RP-HPLC as for 15-LO activity. The detection was made in the negative ion mode for the major ions for 15-HETE (319 m/z) and 13-HODE (295 m/z), respectively.
Inhibition of Aortic 15-LO-I Expression by Antisense Oligonucleotides
Aortas from 1-week-old rabbits were excised, cleaned, and cut into 1-mm rings. Two rings were placed in each cell culture well with 0.5 mL of Krebs solution. The rings were transfected with either scrambled (5'-ggtccttctccaataacgtgg-3') or antisense (5'-gctcatcaacctggaagtcag-3') phosphorothiolated oligonucleotides. Oligofectamine (Invitrogen, 4 µL) was diluted in 11 µL of Opti-MEM (Qiagen). After 10 minutes at room temperature, the oligofectamine mixture was added to the scrambled or antisense oligonucleotides (35 µmol/L) diluted in Opti-MEM to a final volume of 100 µL. The mixture was left for 20 minutes at room temperature. Rings were placed in Krebs solution (325 µL), 100 µL of the mixture overlaid onto the rings, and incubated for 12 hours at 30°C. The tissue was used immediately for Western immunoblotting or vascular reactivity studies.
Isometric Tension in Aortic Rings
Aortic rings were mounted in a 4-chamber wire myograph (Danish MyoTechnology A/S).3 The rings were equilibrated in Krebs solution (in mmol/L, 119 NaCl, 4.7 KCl, 2.5 CaCl2, 1.17 MgSO4, 25 NaHCO3, 1.18 KH2PO4, 0.027 EDTA, and 5.5 glucose) bubbled with 95% O2/5% CO2 at 37°C for 30 minutes under 0.5 g of resting tension (the length-tension maximum). After pretreatment for 15 minutes with L-NA (30 µmol/L) and indomethacin (10 µmol/L), submaximal concentration of serotonin (0.1 to 1 µmol/L) was added to precontract the arteries to 50% to 75% of the maximal KCl contraction. Cumulative concentration-response curves were determined for acetylcholine (109 to 105 mol/L).
Statistical Analysis
Data are expressed as mean±SEM. Significance was evaluated by Student t test or ANOVA followed by the Student-Newman-Kuels multiple comparison test.
| Results |
|---|
|
|
|---|
-actin antibody (data not shown). 15-LO-I immunofluorescence was strongly associated with vascular endothelium (Figure Ia and Ib, available online at http:atvb.ahajournals.org). Smooth muscle cells located close to the endothelial layer were also stained by the 15-LO antibody. No immunoreactivity was observed when the primary antibody was omitted or when antigen-absorbed antiserum was applied (data not shown). Another antirabbit 15-LO-I antiserum (Cayman Chemical) gave similar results (data not shown). These data indicate that transcription and translation of the 15-LO-I gene occurs primarily in rabbit aortic ECs.
|
A RT-PCR/restriction digest strategy was developed to quantify the relative expression of 15-LO and 12-LO. For this purpose, we amplified a 325-bp fragment that contains the functionally most important amino acid difference between the 15-LO-I and the 12-LO (Figure 2). The annealing sequence of the PCR primers was identical for the 2 LO isoforms so that both mRNA species were amplified to the same extent. This PCR product contained a single BstN1 restriction site when the 15-LO-I mRNA was amplified (Figure 2A). In contrast, the restriction site was absent when the 12-LO mRNA constituted the template (Figure 2B). Thus, when the PCR product was digested with BstN1, it was possible to obtain the relative expression of the LO-isoforms (Figure 2C). The PCR product obtained from the control 15-LO plasmid (positive control) was completely digested under these experimental conditions as was the PCR product obtained from aortic mRNA extracts. In contrast, no restriction cleavage was seen when a control plasmid of the 12-LO was used as PCR template (negative control). These data indicate the expression of the 15-LO-I but not 12-LO in rabbit aorta.
|
Aortic 15-LO Activity
Rabbit aortic homogenates and cytosol converted AA and LA into 15-HETE and 13-HODE, respectively. AA was converted by aortic cytosol to a major metabolite comigrating with 15-HETE standard on HPLC (Figure 3A). Liquid chromatography (LC)-electrospray ionization (ESI)-mass spectrometric (MS) analysis of this metabolite showed a major ion of 319 m/z (M-1), confirming it as 15-HETE (Figure 3C). Small amounts of 12-HETE were also formed. LA was metabolized to a metabolite comigrating with 13-HODE. A small amount of 9-HODE was also detected (Figure 3B). LC-ESI-MS analysis indicated a major ion of 295 m/z (M-1) confirming biosynthesis of 13-HODE (Figure 3D). The 15-LO inhibitors, CDC and NDGA, inhibited the synthesis of 15-HETE from AA (Figure 3E) and 13-HODE from LA (Figure 3F).
|
When aortic cytosol was incubated for various times with AA or LA (105 mol/L), the 15-HETE and 13-HODE production increased linearly over 20 minutes (Figure 4A and 4B). The synthesis of 15-HETE and 13-HODE depended on the concentration of AA and LA, respectively, and Michaelis-Menten kinetics were observed (Figure 4C and 4D). We determined Michaelis constant (Km) values of 2.2±0.3 and 23.5±3.3 µmol/L for AA and LA, respectively. The maximum velocity for AA oxygenation was lower than that for LA. Km values of 6.0±2.2 (AA) and 80.2±22.2 µmol/L (LA) were determined for the purified rabbit reticulocyte 15-LO-I (Figure 4E and 4F). For the purified enzyme, maximum velocity for LA was higher than that for AA. Thus, the kinetic characteristics of the rabbit aortic 15-LO were similar to those of the purified 15-LO-I.
|
When AA and LA were added together, LA metabolism to 13-HODE was selectively quantified. AA decreased the synthesis of 13-HODE from LA (50 µmol/L) by 30% and 80% at 1 and 10 µmol/L, respectively (Figure 5A). In contrast, LA inhibited the synthesis of 15-HETE from AA less. LA decreased 15-HETE from AA (20 µmol/L) by 17% and 51% at 1 and 10 µmol/L, respectively (Figure 5B). Interestingly, the Km for AA and LA were only slightly altered by the addition of the other substrate, which may imply a mixed competitive/noncompetitive mode of action. AA strongly decreased LA metabolism (IC50=0.8 µmol/L; Figure 5C). In contrast, LA was a weaker inhibitor of AA metabolism (IC50=6.9 µmol/L; Figure 5D). When aortic cytosol was incubated with 14C-AA, the major metabolites comigrated with 15-HETE, HEETA, and THETA (Figure II, available online at http://atvb.ahajournals.org). 14C-15-HETE production was slightly decreased by the addition of 10 µmol/L LA but not with lower concentration. Unlabeled AA inhibited 14C-15-HETE synthesis in a concentration-related manner. 14C-13-HODE was the major metabolite from 14C-LA. Its production was inhibited by LA and AA with a reduction by 61% with 1 mmol/L AA. These data suggest that AA is preferred as a substrate over LA by the rabbit aortic 15-LO-I.
|
Inhibition of 15-LO-I Expression on Isometric Tension
Determination of the nucleotide sequence of aortic 15-LO cDNA enables us to suppress 15-LO-I expression by antisense oligonucleotide targeting of the Phe353Leu region of the enzyme. The antisense oligonucleotide strongly decreased 15-LO after 12 hours, yet the scrambled oligonucleotide did not affect 15-LO (Figure 6A). Because 11,12,15-THETA mediates acetylcholine-induced relaxations in the rabbit aorta,5,7 we compared the endothelium-dependent relaxation to acetylcholine in antisense and scrambled oligonucleotide-treated aortas. In aortic rings pretreated with indomethacin (10 µmol/L) and L-NA (30 or 300 µmol/L), increasing concentrations of acetylcholine induced relaxation. The control and scrambled oligonucleotide-treated group showed a significant relaxation response to 107 mol/L acetylcholine (Figure 6B). Maximal relaxations at 105 mol/L were 28% for the control and 23% for the scrambled oligonucleotide-treated group. In contrast, aortas treated with 15-LO-I antisense oligonucleotide had a significantly reduced relaxation response to acetylcholine, with only 10% relaxation at 105 mol/L. These data support the importance of 15-LO-I and its metabolites in endothelium-dependent relaxation.
|
| Discussion |
|---|
|
|
|---|
We wanted to determine the specific LO isoform expressed in the vasculature. Three lines of experimental evidence indicate that 15-LO-I but not 12-LO is expressed: (1) the sequence of the PCR product obtained with 12/15-LO-specific primers matched 15-LO-I; (2) activity assays using aortic cytosol revealed 15-HETE as the major metabolite of AA; and (3) our RT-PCR/restriction digestion strategy excluded the expression of 12-LO.
Using in situ hybridization, 12/15-LO is expressed in aorta from atherosclerotic rabbits.30 In addition, we tested for the presence of other 15-LO isoforms. However, we detected neither 12-LO mRNA nor transcripts similar to human 15-LO-II. To determine whether 15-LO-I mRNA is translated into protein in aortic tissue, immunoblotting was performed using 2 specific 15-LO-I antibodies. Both antibodies recognized a single 75-kDa band, the molecular weight of 15-LO-I.17 15-LO-I mRNA, but not protein expression, was reported in human umbilical ECs treated with interleukin 4.31 We detected 15-LO-I mRNA and protein expression from human aortic ECs. Using immunohistochemistry, 15-LO-I was expressed in both rabbit aortic endothelium and smooth muscle cells adjacent to the endothelium, which agrees with the localization of 15-LO mRNA.30 It is interesting that 15-LO is present in smooth muscle cells close to the endothelium but not more distal layers. It is possible that an endothelial factor may induce 15-LO expression in adjacent smooth muscle cells.
The 15-LO-I in rabbit aorta is enzymatically active. Exogenous AA is converted by rabbit aortic cytosol mainly to 15-HETE and LA to 13-HODE. The rabbit 15-LO is a cytosolic enzyme, which translocates to intracellular membranes when the calcium concentration is increased to 1 to 10 µmol/L.17 We also found that aortic 15-LO is located primarily in the cytosol when the calcium concentration is <1 mmol/L (data not shown).
The kinetic characteristics for aortic 15-LO are similar to purified rabbit reticulocyte 15-LO. For both enzyme preparations, Km values were in the lower micromole per liter range.13,14,32,33 15-LO-I, both aortic cytosol and purified enzyme, exhibits a higher affinity for AA than for LA. These data are consistent with other findings, suggesting that AA is a better substrate of mammalian 15-LO than LA.32,34 Endothelial 15-LO metabolizes AA to 15-HPETE, which is additionally metabolized to vasoactive THETA and HEETA.7 A higher affinity of aortic 15-LO-I for AA is consistent with an important role for 15-LO and its AA metabolites in endothelial function.
LO inhibitors, such as CDC, ebselen, and NDGA, block acetylcholine-induced relaxations in aortic rings pretreated with L-NA and indomethacin.5,7 However, these LO inhibitors can also block the activity of 5-, 12-, and 15-LO.21 Thus, studies with these inhibitors may not establish the role of 15-LO in regulating vascular tone. Obtaining the nucleotide sequence of aortic 15-LO allowed us to design antisense oligonucleotides to specifically reduce the expression of 15-LO-I. We suppressed 15-LO-I expression in isolated aortic rings while preserving vascular smooth muscle and endothelial function. Interestingly, vessels treated with an antisense oligonucleotide were less sensitive to acetylcholine stimulation, and the maximum relaxation to acetylcholine was reduced. This strongly supports a role for 15-LO-I in regulating vascular tone.
In summary, our data indicate that rabbit aortic 15-LO activity is attributable to expression of the 15-LO-I in vascular ECs and a subset of smooth muscle cells. This enzyme is responsible for the formation of the vasodilators 15-H-11,12-EETA and 11,12,15-THETA.3,5,7 These 15-LO products mediate AA-induced relaxations and function as endothelium-derived hyperpolarizing factors.3,5,7 Consistent with this conclusion, reducing 15-LO expression with an antisense oligonucleotide decreases relaxation to acetylcholine. These studies indicate that 15-LO-I contributes to regulation of vascular tone in the rabbit aorta.
| Acknowledgments |
|---|
Received July 20, 2005; accepted October 10, 2005.
| References |
|---|
|
|
|---|
2. Singer HA, Peach MJ. Endothelium-dependent relaxation of rabbit aorta. I. Relaxation stimulated by arachidonic acid. J Pharmacol Exp Ther. 1983; 226: 790795.
3. Pfister SL, Spitzbarth N, Edgemond W, Campbell WB. Vasorelaxation by an endothelium-derived metabolite of arachidonic acid. Am J Physiol. 1996; 270: H1021H1030.[Medline] [Order article via Infotrieve]
4. Förstermann U, Alheid U, Frolich JG, Mulsch A. Mechanisms of action of lipoxygenase and cytochrome P-450-mono-oxygenase inhibitors in blocking endothelium-dependent vasodilation. Brit J Pharmacol. 1988; 93: 569578.[Medline] [Order article via Infotrieve]
5. Campbell WB, Spitzbarth N, Gauthier KM, Pfister SL. 11,12,15-Trihydroxyeicosatrienoic acid mediates acetylcholine-induced relaxations in the rabbit aorta. Am J Physiol. 2003; 285: H2648H2456.
6. Pfister SL, Campbell WB. Reduced pulmonary artery vasoconstriction to methacholine in cholesterol-fed rabbits. Hypertension. 1996; 27: 804810.
7. Pfister SL, Spitzbarth N, Nithipatikom K, Edgemond WS, Falck JR, Campbell WB. Identification of 11,14,15- and 11,12,15-trihydroxyeicosatrienoic acids as endothelium-derived relaxing factors of rabbit aorta. J Biol Chem. 1998; 273: 3087930887.
8. Sigal E, Grunberger D, Craik CS, Caughey GH, Nadel JA. Arachidonate 15-lipoxygenase (w-6 lipoxygenase) from human leukocytes. J Biol Chem. 1988; 263: 53285332.
9. Brash AR, Beoglin WE, Chang MS. Discovery of a second 15S-lipoxygenase in humans. Proc Natl Acad Sci U S A. 1997; 94: 61486152.
10. Thiele BJ, Fleming J, Kasturi K, OPrey J, Black E, Chester J, Rapoport SM, Harrison PR. Cloning of a rabbit erythroid-cell-specific lipoxygenase mRNA. Gene. 1987; 57: 111119.[CrossRef][Medline] [Order article via Infotrieve]
11. Kuhn H, Thiele BJ. Arachidonate 15-lipoxygenase. J Lipid Mediat Cell Signal. 1995; 12: 157170.[CrossRef][Medline] [Order article via Infotrieve]
12. Salzmann-Reinhardt U, Kuhn H, Wiesner R, Rapoport S. Metabolism of polyunsaturated fatty acids by rabbit reticulocytes. Eur J Biochem. 1985; 153: 189194.[Medline] [Order article via Infotrieve]
13. Ivanov I, Schwarz K, Holzhutter HG, Myagkova G, Kuhn H. w-Oxidation impairs oxidizability of polyenoic fatty acids by 15-lipoxygenases: consequences for substrate orientation at the active site. Biochem J. 1998; 336: 345352.[Medline] [Order article via Infotrieve]
14. Kozak KR, Gupta RA, Moody JS, Ji C, Boeglin WE, Dubois RN, Brash AR, Marnett LJ. 15-Lipoxygenase metabolism of 2-arachidonylglycerol. J Biol Chem. 2002; 277: 2327823286.
15. Brash AR, Ingram CD, Harris TM. Analysis of a specific oxygenation reaction of soybean lipoxygenase-1 with fatty acids esterified in phospholipids. Biochemistry. 1987; 26: 54655471.[CrossRef][Medline] [Order article via Infotrieve]
16. Murray JJ, Brash AR. Rabbit reticulocyte lipoxygenase catalyzes specific 12(s) and 15(s) oxygenation of arachidonyl-phosphatidylcholine. Arch Biochem Biophys. 1988; 265: 514523.[CrossRef][Medline] [Order article via Infotrieve]
17. Brinckmann R, Schnurr K, Heydeck D, Rosenbach T, Kolde G, Kuhn H. Membrane translocation of 15-lipoxygenase in hematopietic cells is calcium-dependent and activates the oxygenase activity of the enzyme. Blood. 1998; 91: 6474.
18. Brash AR, Jisaka M, Boeglin WE, Chang MS, Keeney DS, Nanney LB, Kasper S, Matusik RJ, Olson SJ, Shappell SB. Investigation of a second 15S-lipoxygenase in humans and its expression in epithelial tissues. Adv Exp Med Biol. 1999; 469: 8389.[Medline] [Order article via Infotrieve]
19. Berger M, Schwarz K, Thiele H, Reimann I, Huth A, Borngraber S, Kuhn H, Thiele BJ. Simultaneous expression of leukocyte-type 12-lipoxygenase and reticulocyte-type 15-lipoxygenase in rabbits. J Mol Biol. 1998; 278: 935948.[CrossRef][Medline] [Order article via Infotrieve]
20. Pfister SL, Schmitz JM, Willerson JT, Campbell WB. Characterization of arachidonic acid metabolism in Watanabe Heritable Hyperlipidemic (WHHL) and New Zealand White (NZW) rabbit aortas. Prostaglandins. 1988; 36: 515531.[CrossRef][Medline] [Order article via Infotrieve]
21. Salari H, Braquet P, Borgeat P. Comparative effects of indomethacin, acetylenic acids, 15-HETE, nordihydroguaiaretic acid and BW755C on the metabolism of arachidonic acid in human leukocytes and platelets. Prostaglandins Leukot Med. 1984; 13: 5360.[CrossRef][Medline] [Order article via Infotrieve]
22. Tang X, Spitzbarth N, Kuhn H, Chaitidis P, Campbell WB. Interleukin-13 upregulates vasodilatory 15-lipoxygenase eicosanoids in rabbit aorta. Arterioscler Thromb Vasc Biol. 2003; 23: 17681774.
23. Fleming J, Thiele BJ, Chester J, OPrey J, Janetzki S, Aitken A, Anton IA, Rapoport SM, Harrison PR. The complete sequence of the rabbit erythroid cell-specific 15-lipoxygenase mRNA: comparison of the predicted amino acid sequence of the erythrocyte lipoxygenase with other lipoxygenases. Gene. 1989; 79: 181188.[CrossRef][Medline] [Order article via Infotrieve]
24. Nithipatikom K, Grall AJ, Harder DR, Falck JR, Campbell WB. Liquid chromatographic-electrospray ionization-mass spectrometric analysis of cytochrome P-450 metabolites of arachidonic acid. Anal Chem. 2001; 298: 327336.
25. Förstermann U, Neufang B. The endothelium-dependent vasodilator effect of acetylcholine: Characterization of the endothelial relaxing factor with inhibitors of arachidonic acid metabolism. Europ J Pharmacol. 1984; 103: 6570.[CrossRef][Medline] [Order article via Infotrieve]
26. Van Diest MJ, Verbeuren TJ, Herman AG. 15-Lipoxygenase metabolites of arachidonic acid evokes contractions and relaxations in isolated canine arteries. J Pharmacol Exp Ther. 1991; 256: 194203.
27. Vargas UR, Wroblewska B, dAlarcao M, Matsuda SP, Corey EJ, Cunard CM, Ramwell PW. Relaxing effect of 15-lipoxygenase products of arachidonic acid on rat aorta. J Pharmacol Exp Ther. 1989; 242: 945949.
28. Zink MH, Oltman CL, Lu T, Katakam PVG, Kaduce TL, Lee HC, Dellsperger KC, Spector AA, Myers PR, Weintraub NL. 12-Lipoxygenase in porcine coronary microcirculation: implications for coronary vasoregulation. Am J Physiol. 2001; 280: H693H704.
29. Miller AW, Katakam PVG, Lee HC, Tulbert CD, Busija DW, Weintraub NL. Arachidonic acid-induced vasodilation of rat small mesenteric arteries is lipoxygenase-dependent. J Pharmacol Exp Ther. 2003; 304: 139144.
30. Hugou I, Blin P, Henri J, Daret D, Larrue J. 15-Lipoxygenase expression in smooth muscle cells from atherosclerotic rabbit aortas. Atherosclerosis. 1995; 113: 189195.[CrossRef][Medline] [Order article via Infotrieve]
31. Lee YW, Kuhn H, Kaiser S, Kennig G, Daugherty A, Toborek M. Interleukin-4 induces transcription of the 15-lipoxygenase-I gene in human endothelial cells. J Lipid Res. 2001; 42: 783791.
32. Schwarz K, Borngraber S, Anton M, Kuhn H. Probing the substrate alignment at the active site of 15-lipoxygenases by targeted substrate modification and site-directed mutagenesis. Evidence for an inverse substrate orientation. Biochemistry. 1998; 37: 1532715335.[CrossRef][Medline] [Order article via Infotrieve]
33. Mogul R, Holman TR. Inhibition studies of soybean and human 15-lipoxygenase with long-chain alkenyl sulfate substrates. Biochemistry. 2001; 40: 43914397.[CrossRef][Medline] [Order article via Infotrieve]
34. Soberman RJ, Harper TW, Betteridge D, Lewis RA, Austen KF. Characterization and separation of the arachidonic acid 5-lipoxygenase and linoleic acid omega-6 lipoxygenase (arachidonic acid 15-lipoxygenase) of human polymorphonuclear leukocytes. J Biol Chem. 1985; 260: 45084515.
This article has been cited by other articles:
![]() |
N. T. Aggarwal, S. L. Pfister, and W. B. Campbell Hypercholesterolemia Enhances 15-Lipoxygenase-Mediated Vasorelaxation and Acetylcholine-Induced Hypotension Arterioscler. Thromb. Vasc. Biol., December 1, 2008; 28(12): 2209 - 2215. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. T. Aggarwal, K. M. Gauthier, and W. B. Campbell 15-Lipoxygenase metabolites contribute to age-related reduction in acetylcholine-induced hypotension in rabbits Am J Physiol Heart Circ Physiol, July 1, 2008; 295(1): H89 - H96. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Chawengsub, N. T. Aggarwal, K. Nithipatikom, K. M. Gauthier, S. Anjaiah, B. D. Hammock, J. R. Falck, and W. B. Campbell Identification of 15-hydroxy-11,12-epoxyeicosatrienoic acid as a vasoactive 15-lipoxygenase metabolite in rabbit aorta Am J Physiol Heart Circ Physiol, March 1, 2008; 294(3): H1348 - H1356. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. M. Gauthier, Y. Chawengsub, D. H. Goldman, R. E. Conrow, S. Anjaiah, J. R. Falck, and W. B. Campbell 11(R),12(S),15(S)-trihydroxyeicosa-5(Z),8(Z),13(E)-trienoic acid: an endothelium-derived 15-lipoxygenase metabolite that relaxes rabbit aorta Am J Physiol Heart Circ Physiol, March 1, 2008; 294(3): H1467 - H1472. [Abstract] [Full Text] [PDF] |
||||
![]() |
X. Tang, N. Aggarwal, B. B. Holmes, H. Kuhn, and W. B. Campbell Age-related decrease in 15-lipoxygenase contributes to reduced vasorelaxation in rabbit aorta Am J Physiol Heart Circ Physiol, February 1, 2008; 294(2): H679 - H687. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. T. Aggarwal, Y. Chawengsub, K. M. Gauthier, H. Viita, S. Yla-Herttuala, and W. B. Campbell Endothelial 15-Lipoxygenase-1 Overexpression Increases Acetylcholine-Induced Hypotension and Vasorelaxation in Rabbits Hypertension, February 1, 2008; 51(2): 246 - 251. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
ATVB Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2006 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |